$WVE
Wave Life Sciences Ltd. Stock $wve

$wve Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022016653 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$285.0K	$375.0K	$1.750M
YoY Change	-99.22%	-86.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.61M	$12.81M	$12.37M
YoY Change	-10.31%	16.75%	22.76%
% of Gross Profit
Research & Development	$27.58M	$29.73M	$27.47M
YoY Change	-11.29%	-6.01%	-17.74%
% of Gross Profit
Depreciation & Amortization	$1.637M	$1.695M	$1.730M
YoY Change	-11.37%	-11.12%	-11.19%
% of Gross Profit
Operating Expenses	$39.18M	$42.54M	$39.84M
YoY Change	-11.01%	-0.15%	-8.34%
Operating Profit	-$38.90M	-$42.16M	-$38.09M
YoY Change	411.36%	5.87%	-12.37%
Interest Expense	$596.0K	$124.0K	$26.00K
YoY Change	9833.33%	1450.0%	160.0%
% of Operating Profit
Other Income/Expense, Net	-$105.0K	$868.0K	$280.0K
YoY Change	-107.66%	-18.27%	-72.19%
Pretax Income	-$39.00M	-$41.30M	-$37.81M
YoY Change	526.07%	6.53%	-10.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$39.00M	-$41.30M	-$37.81M
YoY Change	526.07%	6.53%	-10.95%
Net Earnings / Revenue	-13685.61%	-11012.27%	-2160.8%
Basic Earnings Per Share	-$0.42	-$0.62	-$0.62
Diluted Earnings Per Share	-$0.42	-$0.62	-$624.9K
COMMON SHARES
Basic Shares Outstanding	86.82M	66.48M	60.84M
Diluted Shares Outstanding	93.90M	66.48M	60.52M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$122.0M	$148.2M	$111.7M
YoY Change	-1.53%	3.01%	-24.77%
Cash & Equivalents	$96.95M	$123.2M	$61.71M
Short-Term Investments	$25.04M	$25.00M	$50.00M
Other Short-Term Assets	$2.017M	$6.555M	$5.730M
YoY Change	-82.6%	2.37%	-64.19%
Inventory
Prepaid Expenses	$7.419M	$5.396M	$6.940M
Receivables
Other Receivables
Total Short-Term Assets	$131.4M	$160.1M	$124.4M
YoY Change	-16.81%	0.43%	-36.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.55M	$19.81M	$21.05M
YoY Change	-52.01%	-51.72%	-51.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.698M	$4.606M	$4.336M
YoY Change	-4.35%	-22.58%	-13.28%
Total Long-Term Assets	$50.08M	$53.21M	$42.98M
YoY Change	17.76%	13.25%	-10.65%
TOTAL ASSETS
Total Short-Term Assets	$131.4M	$160.1M	$124.4M
Total Long-Term Assets	$50.08M	$53.21M	$42.98M
Total Assets	$181.5M	$213.3M	$167.4M
YoY Change	-9.48%	3.35%	-31.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.93M	$11.17M	$9.853M
YoY Change	114.08%	29.04%	-26.47%
Accrued Expenses	$1.907M	$3.473M	$3.152M
YoY Change	-43.65%	7.42%	-69.98%
Deferred Revenue	$32.34M	$37.47M	$36.43M
YoY Change		54.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$64.26M	$64.08M	$58.49M
YoY Change	103.09%	37.16%	20.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$113.9M	$110.4M	$868.0K
YoY Change	-13.12%	-15.05%	-99.35%
Total Long-Term Liabilities	$113.9M	$110.4M	$101.1M
YoY Change	-13.12%	-15.05%	-24.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.26M	$64.08M	$58.49M
Total Long-Term Liabilities	$113.9M	$110.4M	$101.1M
Total Liabilities	$178.2M	$174.5M	$159.5M
YoY Change	9.47%	-1.24%	-12.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$923.6M	-$884.6M	-$843.3M
YoY Change
Common Stock	$802.7M	$802.4M	$751.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.519M	$30.95M	-$53.00K
YoY Change
Total Liabilities & Shareholders Equity	$181.5M	$213.3M	$167.4M
YoY Change	-9.48%	3.35%	-31.01%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$39.00M	-$41.30M	-$37.81M
YoY Change	526.07%	6.53%	-10.95%
Depreciation, Depletion And Amortization	$1.637M	$1.695M	$1.730M
YoY Change	-11.37%	-11.12%	-11.19%
Cash From Operating Activities	-$25.65M	-$28.82M	-$39.87M
YoY Change	-9.01%	206.75%	-10.15%
INVESTING ACTIVITIES
Capital Expenditures	-$457.0K	-$492.0K	$208.0K
YoY Change	366.33%	45.99%	92.59%
Acquisitions
YoY Change
Other Investing Activities	-$44.00K	$25.11M	-$50.00M
YoY Change
Cash From Investing Activities	-$501.0K	$24.61M	-$50.21M
YoY Change	411.22%	-7403.86%	46388.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.00K	65.80M	1.316M
YoY Change	-99.8%	1204.0%	-84.77%
NET CHANGE
Cash From Operating Activities	-25.65M	-28.82M	-39.87M
Cash From Investing Activities	-501.0K	24.61M	-50.21M
Cash From Financing Activities	17.00K	65.80M	1.316M
Net Change In Cash	-26.13M	61.59M	-88.85M
YoY Change	31.09%	-1414.1%	147.07%
FREE CASH FLOW
Cash From Operating Activities	-$25.65M	-$28.82M	-$39.87M
Capital Expenditures	-$457.0K	-$492.0K	$208.0K
Free Cash Flow	-$25.19M	-$28.33M	-$40.08M
YoY Change	-10.31%	212.73%	-9.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001631574
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37627
	dei	Entity Registrant Name EntityRegistrantName	WAVE LIFE SCIENCES LTD.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	U0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Straits View #12-00
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Marina One
	dei	Entity Address City Or Town EntityAddressCityOrTown	East Tower
	dei	Entity Address Country EntityAddressCountry	SG
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	018936
	dei	City Area Code CityAreaCode	+65
	dei	Local Phone Number LocalPhoneNumber	6236 3388
	dei	Security12b Title Security12bTitle	$0 Par Value Ordinary Shares
	dei	Trading Symbol TradingSymbol	WVE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86820111
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123163000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150564000
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	25000000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5396000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6584000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	6555000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5416000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	160114000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	162564000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19808000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22266000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	28791000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18378000
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3651000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3651000
CY2022Q2	us-gaap	Other Assets OtherAssets	955000
CY2021Q4	us-gaap	Other Assets OtherAssets	148000
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	53205000
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	44443000
CY2022Q2	us-gaap	Assets Assets	213319000
CY2021Q4	us-gaap	Assets Assets	207007000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11168000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7281000
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11085000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14861000
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	37466000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	37098000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4363000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4961000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	64082000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	64201000
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	75256000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	77479000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	35160000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24955000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	110416000
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	102434000
CY2022Q2	us-gaap	Liabilities Liabilities	174498000
CY2021Q4	us-gaap	Liabilities Liabilities	166635000
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0
CY2022Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	3901348
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	3901348
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3901348
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	3901348
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7874000
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7874000
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86724658
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86724658
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59841116
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59841116
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	802449000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	749851000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	113169000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87980000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-47000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	181000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-884624000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805514000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30947000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32498000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	213319000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207007000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	375000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2776000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2125000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2776000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29733000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31635000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57203000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65028000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12806000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10969000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25180000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21047000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	42539000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	42604000
	us-gaap	Operating Expenses OperatingExpenses	82383000
	us-gaap	Operating Expenses OperatingExpenses	86075000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-42164000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-39828000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-80258000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83299000
CY2022Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	124000
CY2021Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	8000
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	150000
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	19000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	744000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1054000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	998000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2050000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	868000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1062000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1148000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2069000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41296000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38766000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79110000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-81230000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41296000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-38766000
	us-gaap	Net Income Loss NetIncomeLoss	-79110000
	us-gaap	Net Income Loss NetIncomeLoss	-81230000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.65
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66479293
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49973185
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66479293
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49973185
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63514426
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63514426
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49220140
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49220140
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41296000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-38766000
	us-gaap	Net Income Loss NetIncomeLoss	-79110000
	us-gaap	Net Income Loss NetIncomeLoss	-81230000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-142000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-228000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-120000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41438000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38766000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79338000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81350000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	82778000
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	4063000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	200000
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	336000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-120000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-42464000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	52821000
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2722000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-38766000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	21842000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	32498000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3971000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	37000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	174000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-86000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37814000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-53000
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	51220000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	14268000
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	6950000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-142000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41296000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30947000
	us-gaap	Profit Loss ProfitLoss	-79110000
	us-gaap	Profit Loss ProfitLoss	-81230000
	wve	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	1593000
	wve	Amortization Of Right Of Use Assets AmortizationOfRightOfUseAssets	1043000
	us-gaap	Depreciation Depreciation	3425000
	us-gaap	Depreciation Depreciation	3857000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10921000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6785000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30000000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1188000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1246000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1946000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3475000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3264000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5251000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3776000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2048000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1855000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2776000
	wve	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2399000
	wve	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1792000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-135000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68695000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53776000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	700000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	447000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	106000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	50000000
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	25000000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25594000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-447000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51464000
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	14336000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	174000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	336000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67116000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13686000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-228000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-120000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27401000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40657000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	154215000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188148000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126814000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	147491000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12006000
	wve	Offering Costs In Accounts Payable OfferingCostsInAccountsPayable	311000
	wve	Offering Costs In Accounts Payable OfferingCostsInAccountsPayable	57000
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	148200000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p>
CY2022Q2	wve	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0
CY2022Q2	wve	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0
	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	On June 16, 2022, the Company closed an underwritten offering (the “June 2022 Offering”) in which the Company issued and sold 25,464,483 of the Company’s ordinary shares at a price of $2.15 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 7,093,656 of the Company’s ordinary shares at an offering price of $2.1499 per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders’ equity within additional paid-in capital. The gross proceeds to the Company were $70.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds of the June 2022 Offering were approximately $65.5 million. The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of ordinary shares outstanding or more than 19.99% of the combined voting power of the Company’s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The lease for the additional space commenced on October 1, 2021, with a term of five years and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the “Additional Cambridge Lease”).
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6574000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10181000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3473000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3571000
CY2022Q2	wve	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1038000
CY2021Q4	wve	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1109000
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11085000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14861000
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4500000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4500000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.

Files In Submission

Name	View Source	Status
0000950170-22-016653-index-headers.html	Edgar Link	pending
0000950170-22-016653-index.html	Edgar Link	pending
0000950170-22-016653.txt	Edgar Link	pending
0000950170-22-016653-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img55497064_0.jpg	Edgar Link	pending
img55497064_1.jpg	Edgar Link	pending
img55497064_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wve-20220630.htm	Edgar Link	pending
wve-20220630.xsd	Edgar Link	pending
wve-ex10_1.htm	Edgar Link	pending
wve-ex31_1.htm	Edgar Link	pending
wve-ex31_2.htm	Edgar Link	pending
wve-ex32.htm	Edgar Link	pending
wve-20220630_cal.xml	Edgar Link	unprocessable
wve-20220630_lab.xml	Edgar Link	unprocessable
wve-20220630_pre.xml	Edgar Link	unprocessable
wve-20220630_htm.xml	Edgar Link	completed
wve-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WVE
Wave Life Sciences Ltd. Stock $wve

2022 Q3 Form 10-Q Financial Statement

#000095017022016653 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WVE Wave Life Sciences Ltd. Stock $wve

2022 Q3 Form 10-Q Financial Statement

#000095017022016653 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WVE
Wave Life Sciences Ltd. Stock $wve